Details of the Drug Combination

General Information of Drug Combination (ID: DC6UT62)

Drug Combination Name

Picoplatin ER819762

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

ER819762 DMSG91J

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: HCT-15

Zero Interaction Potency (ZIP) Score: 1.69

Bliss Independence Score: 5.34

Loewe Additivity Score: 2.87

LHighest Single Agent (HSA) Score: 1.95

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Picoplatin

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]
Small-cell lung cancer	2C25.Y	Phase 3	[2]

Indication(s) of ER819762

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

ER819762 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Antagonist	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Glioma	DC01GS5	SF-268	Investigative	[5]
Adenocarcinoma	DCT728J	OVCAR3	Investigative	[1]
Adenocarcinoma	DC0DRA3	NCIH23	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCPTV8N	OVCAR-4	Investigative	[1]
Lung adenocarcinoma	DCKU36B	HOP-62	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCPYCTU	NCI-H322M	Investigative	[1]
Prostate carcinoma	DCIKLYZ	PC-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4	A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.